Position in FOLD
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$13,630,719
+$5,756,711 QoQ
Shares Held
942,650
+70.5% QoQ
Ownership
0.300%
of shares outstanding
% of Portfolio
0.10%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in FOLD Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026GABELLI FUNDS LLC holds $96,689,277 across 29 Biotechnology names. FOLD ranks #3 (14.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ACLX |
Arcellx, Inc.
|
195,900 | $22,493,238 | |
| 2 | TERN |
Terns Pharmaceuticals, Inc.
|
271,857 | $14,332,301 | |
| 3 | FOLD |
AMICUS THERAPEUTICS, INC.
This page
|
942,650 | $13,630,719 | |
| 4 | APLS |
Apellis Pharmaceuticals, Inc.
|
321,200 | $12,921,876 | |
| 5 | DAWN |
Day One Biopharmaceuticals, Inc.
|
464,097 | $9,950,239 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
65,300 | $4,849,178 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
7,920 | $3,536,596 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
46,200 | $2,985,906 |
All Filings in FOLD
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $13,630,719 | 942,650 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $7,874,008 | 552,950 | Shares | Sole | 2026-02-05 | |
| No filing history on record for this holder in this stock. | ||||||